ElMindA Raises $28 Million in Series C Financing to Accelerate its BNA™ Technology Adoption

ElMindA Raises Million in Series C Financing to Accelerate its BNA™ Technology Adoption

CHICAGO–(BUSINESS WIRE)–ElMindA Ltd., a pioneer in neuroscience-based technology for analyzing brain network functionality, today announced the successful completion of an oversubscribed $28 million Series C financing round. The global syndicate of investors in this round includes Shanda Group, New England Patriots owner – The Kraft Group, Wexford Capital, WR Hambrecht & Co, Palisade Capital Management, OurCrowd and Healthcrest AG and others. Proceeds will be used to continue advancement of ElMindA’s proprietary BNA™ (Brain Network Activation) system, which uses multi-channel EEG-ERP electrophysiology technology to provide a more accurate, objective assessment of brain functionality over time. ElMindA will also use the funds for commercial and clinical adoption following BNA’s 2014 FDA clearance in the U.S., and CE Mark approval in Europe for brain function assessment. “We are thrilled to have attracted such…


Link to Full Article: ElMindA Raises Million in Series C Financing to Accelerate its BNA™ Technology Adoption